norfloxacin has been researched along with Neutropenia in 19 studies
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A total of 63 neutropenic patients receiving cytotoxic therapy for acute leukemia were randomly allocated to receive norfloxacin (400 mg every 12 hours) or cotrimoxazole (160/800 mg every 12 hours) to prevent bacterial infection." | 9.06 | Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. The trade-off for reduced gram-negative sepsis. ( Bow, EJ; Louie, TJ; Rayner, E, 1988) |
| "In a randomized study comparing cotrimoxazole plus colistin with ciprofloxacin, each in combination with nonabsorbable antimycotics, the incidence of major infections in terms of septicemias and pneumonias as well as of minor infections and episodes of unexplained fever (FUO) was higher in patients treated with ciprofloxacin." | 6.16 | Prevention of infection in acute leukemia. ( Daenen, S; de Pauw, BE; de Vries-Hospers, HG; Dekker, AW; Donnelly, JP; Gaus, W; Haralambie, E; Kern, W; Konrad, H; Maschmeyer, G, 1990) |
| "More patients receiving ciprofloxacin did not develop fever during neutropenia and did not receive antibiotics (34%) compared with those receiving norfloxacin (25%) (P = 0." | 5.07 | Prevention of bacterial infection in neutropenic patients with hematologic malignancies. A randomized, multicenter trial comparing norfloxacin with ciprofloxacin. The GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. ( , 1991) |
| " The treatment of 37 initial febrile episodes (12 cases of septicemia, 7 infectious sites and 38 cases of fever of unknown origin) in 33 neutropenic patients (PMN leucocytes less than 500/mm3) using the combination of a third generation cephalosporin (cefotaxime or ceftazidime) and a new quinolone (pefloxacin) resulted in an 86% immediate success rate (32 cases/37)." | 5.06 | [Combination of a 3d-generation cephalosporin (cefotaxime or ceftazidime) and a new quinolone (pefloxacine) in the treatment of febrile episodes in neutropenic diseases (37 cases)]. ( Bielefeld, P; Caillot, D; Guy, H; Kazmierczak, A; Portier, H; Solary, E, 1987) |
| "A total of 63 neutropenic patients receiving cytotoxic therapy for acute leukemia were randomly allocated to receive norfloxacin (400 mg every 12 hours) or cotrimoxazole (160/800 mg every 12 hours) to prevent bacterial infection." | 5.06 | Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. The trade-off for reduced gram-negative sepsis. ( Bow, EJ; Louie, TJ; Rayner, E, 1988) |
| "To prevent bacterial infections in the neutropenic post-transplant period, norfloxacin 400mg twice daily was administered as oral prophylaxis to 44 marrow recipients isolated in laminar airflow rooms (LAFRs)." | 3.67 | Norfloxacin prophylaxis for neutropenic patients undergoing bone marrow transplantation. ( Aversa, F; Bucaneve, G; Del Favero, A; Felicini, R; Greco, M; Martelli, MF; Menichetti, F; Moretti, MV; Pasquarella, C, 1989) |
| "Norfloxacin has been compared to placebo (136 patients), sulfamethoxazole plus trimethoprim (SXT, 72 patients) and oral vancomycin plus colistin (V/C, 61 patients) for the prevention of alimentary tract-associated infections during and after induction chemotherapy." | 2.66 | The tolerability profile of prophylactic norfloxacin in neutropenic patients. ( Corrado, ML; Hesney, M; Struble, WE, 1988) |
| "Norfloxacin treatment resulted in clinical cure or improvement in 84 percent of patients and eradicated the etiologic pathogen(s) 52 percent of the time." | 1.27 | Compassionate use of norfloxacin. ( Corrado, ML; Heseltine, PN, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (47.37) | 18.7374 |
| 1990's | 10 (52.63) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carratalá, J | 1 |
| Fernández-Sevilla, A | 1 |
| Tubau, F | 1 |
| Callis, M | 1 |
| Gudiol, F | 1 |
| Mori, S | 1 |
| Ohashi, K | 1 |
| Akiyama, H | 1 |
| Shoji, H | 1 |
| Sato, H | 1 |
| Tanikawa, S | 1 |
| Sakamaki, H | 1 |
| Onozawa, Y | 1 |
| Del Favero, A | 4 |
| Menichetti, F | 3 |
| Bow, EJ | 2 |
| Mandell, LA | 1 |
| Louie, TJ | 2 |
| Feld, R | 1 |
| Palmer, M | 1 |
| Zee, B | 1 |
| Pater, J | 1 |
| Abanmi, N | 1 |
| Zaghloul, I | 1 |
| El Sayed, N | 1 |
| Al-Khamis, KI | 1 |
| Martino, R | 1 |
| Subira, M | 1 |
| Altés, A | 1 |
| López, R | 1 |
| Sureda, A | 1 |
| Domingo-Albós, A | 1 |
| Pericas, R | 1 |
| Brunet, S | 1 |
| Brodsky, A | 1 |
| Melero, M | 1 |
| Vay, C | 1 |
| D'Antonio, D | 2 |
| Iacone, A | 1 |
| Fioritoni, G | 1 |
| Betti, S | 1 |
| Dell'Isola, M | 1 |
| Quaglietta, AM | 1 |
| Accorsi, P | 1 |
| Pantalone, V | 1 |
| Recchia, A | 1 |
| Piergallini, A | 1 |
| Maschmeyer, G | 1 |
| Daenen, S | 1 |
| de Pauw, BE | 1 |
| de Vries-Hospers, HG | 1 |
| Dekker, AW | 1 |
| Donnelly, JP | 1 |
| Gaus, W | 1 |
| Haralambie, E | 1 |
| Kern, W | 1 |
| Konrad, H | 1 |
| Martino, P | 1 |
| Bucaneve, G | 3 |
| Micozzi, A | 1 |
| Minetti, B | 1 |
| Ricci, P | 1 |
| Landonio, G | 1 |
| Montillo, M | 1 |
| Malleo, C | 1 |
| Obana, Y | 1 |
| Nishino, T | 1 |
| Felicini, R | 1 |
| Aversa, F | 1 |
| Greco, M | 1 |
| Pasquarella, C | 1 |
| Moretti, MV | 1 |
| Martelli, MF | 1 |
| Guy, H | 1 |
| Caillot, D | 1 |
| Solary, E | 1 |
| Bielefeld, P | 1 |
| Portier, H | 1 |
| Kazmierczak, A | 1 |
| Corrado, ML | 2 |
| Struble, WE | 1 |
| Hesney, M | 1 |
| Rayner, E | 1 |
| Lee, C | 1 |
| Ronald, AR | 1 |
| Heseltine, PN | 1 |
| Patoia, L | 1 |
| Guerciolini, R | 1 |
2 reviews available for norfloxacin and Neutropenia
| Article | Year |
|---|---|
Prevention of infection in acute leukemia.
Topics: Acute Disease; Anti-Bacterial Agents; Ciprofloxacin; Colistin; Drug Therapy, Combination; Humans; In | 1990 |
Norfloxacin: its potential in clinical practice.
Topics: Bacterial Infections; Diarrhea; Gonorrhea; Humans; Neutropenia; Norfloxacin; Travel; Urinary Tract I | 1987 |
9 trials available for norfloxacin and Neutropenia
| Article | Year |
|---|---|
Tosulfloxacin versus norfloxacin for prevention of infections in chemotherapy-induced neutropenic patients.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Antineoplastic Agents; Bacterial Infections; Drug Ev | 1994 |
Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented gram-positive activity on infectious morbidity. National Cancer Institute of Canada Clinical Trials Group.
Topics: Adult; Aged; Anti-Infective Agents; Antineoplastic Agents; Bacteremia; Colony Count, Microbial; Fema | 1996 |
Comparison of norfloxacin and pefloxacin in the prophylaxis of bacterial infection in neutropenic cancer patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bacteremia; Bacterial Infections; Female; Fever; Hum | 1992 |
Prevention of bacterial infection in neutropenic patients with hematologic malignancies. A randomized, multicenter trial comparing norfloxacin with ciprofloxacin. The GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Female; Fever; | 1991 |
Prevention of infection in acute leukemia.
Topics: Acute Disease; Anti-Bacterial Agents; Ciprofloxacin; Colistin; Drug Therapy, Combination; Humans; In | 1990 |
[Prophylaxis using quinolones in neutropenic patients. Preliminary results of a cooperative study by the Grupo Italiano Malattie Ematologiche maligne dell'adulto (GIMEMEA)].
Topics: Agranulocytosis; Anti-Bacterial Agents; Bacterial Infections; Bone Marrow Transplantation; Ciproflox | 1989 |
[Combination of a 3d-generation cephalosporin (cefotaxime or ceftazidime) and a new quinolone (pefloxacine) in the treatment of febrile episodes in neutropenic diseases (37 cases)].
Topics: Agranulocytosis; Anti-Infective Agents; Cefotaxime; Ceftazidime; Drug Evaluation; Drug Therapy, Comb | 1987 |
The tolerability profile of prophylactic norfloxacin in neutropenic patients.
Topics: Agranulocytosis; Bacterial Infections; Clinical Trials as Topic; Colistin; Diarrhea; Gastrointestina | 1988 |
Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. The trade-off for reduced gram-negative sepsis.
Topics: Acute Disease; Adult; Antineoplastic Agents; Bacterial Infections; Clinical Trials as Topic; Drug Co | 1988 |
9 other studies available for norfloxacin and Neutropenia
| Article | Year |
|---|---|
Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin.
Topics: Adult; Aged; Aged, 80 and over; Bacteremia; Drug Resistance, Microbial; Escherichia coli Infections; | 1995 |
The new fluorinated quinolones for antimicrobial prophylaxis in neutropenic cancer patients.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Therapy, Combination; Gram-Negativ | 1993 |
Determination of pefloxacin and its main active metabolite in human serum by high-performance liquid chromatography.
Topics: Anti-Infective Agents; Chromatography, High Pressure Liquid; Humans; Neutropenia; Norfloxacin; Peflo | 1996 |
Effect of discontinuing prophylaxis with norfloxacin in patients with hematologic malignancies and severe neutropenia. A matched case-control study of the effect on infectious morbidity.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Bacteremia; Bacterial Infect | 1998 |
[Methicillin-resistant Staphylococcus aureus infection in neutropenic patients during norfloxacin prophylaxis].
Topics: Adult; Fatal Outcome; Female; Humans; Immunocompromised Host; Methicillin Resistance; Middle Aged; N | 1992 |
In vivo activity of ciprofloxacin, ofloxacin, norfloxacin and pipemidic acid against Escherichia coli infections in mice.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Escherichia coli Infections; Female; Mice; Microbial | 1989 |
Norfloxacin prophylaxis for neutropenic patients undergoing bone marrow transplantation.
Topics: Adolescent; Adult; Agranulocytosis; Bacterial Infections; Bone Marrow Transplantation; Child; Enviro | 1989 |
Compassionate use of norfloxacin.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections | 1987 |
Norfloxacin and neutropenia.
Topics: Adult; Agranulocytosis; Female; Humans; Neutropenia; Norfloxacin | 1987 |